☆ 4.7 Letter

COVID-19 morbidity decreases with tixagevimab-cilgavimab preexposure prophylaxis in kidney transplant recipient nonresponders or low-vaccine responders

KIDNEY INTERNATIONAL (2022)

Related references

Note: Only part of the references are listed.
Letter Urology & Nephrology

Pre-exposure prophylaxis with 300 mg Evusheld elicits limited neutralizing activity against the Omicron variant

Ilies Benotmane et al.

KIDNEY INTERNATIONAL (2022)

Add to Collection
Letter Urology & Nephrology

Efficacy of anti-SARS-CoV-2 monoclonal antibody prophylaxis and vaccination on the Omicron variant of COVID-19 in kidney transplant recipients

Dominique Bertrand et al.

KIDNEY INTERNATIONAL (2022)

Add to Collection
News Item Infectious Diseases

Research in brief

Sharmila Devi

LANCET INFECTIOUS DISEASES (2022)

Add to Collection
Article Medicine, General & Internal

Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19

Myron J. Levin et al.

Summary: A single dose of AZD7442 showed efficacy in preventing Covid-19 without evident safety concerns. The study suggests that AZD7442 may provide potential protection for individuals who have an inadequate response to vaccination or an increased risk of exposure.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection
Letter Medicine, General & Internal

Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2

Emi Takashita et al.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection
Article Multidisciplinary Sciences

Antibody evasion properties of SARS-CoV-2 Omicron sublineages

Sho Iketani et al.

Summary: The identification of the Omicron variant of SARS-CoV-2 in Botswana in November 2021 sparked concern due to the spike protein alterations that could potentially evade antibodies. Further studies showed that the Omicron sublineages, BA.1+R346K and BA.2, are antigenically similar to the wild-type virus and pose similar risks to the effectiveness of current vaccines. BA.2 also demonstrated resistance to many neutralizing monoclonal antibodies, highlighting the challenges in developing effective therapeutic options.

NATURE (2022)

Add to Collection
Article Urology & Nephrology

Antibody and T Cell Response to SARS-CoV-2 Messenger RNA BNT162b2 Vaccine in Kidney Transplant Recipients and Hemodialysis Patients

Dominique Bertrand et al.

Summary: Immunization with BNT162b2 appears to be more effective in HDPs, with the immune response in KTRs potentially influenced by immunosuppressive medications. Current vaccinal strategies for KTRs may not provide adequate protection against COVID-19 and may need further improvement.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2021)

Add to Collection
Article Urology & Nephrology

An initial report from the French SOT COVID Registry suggests high mortality due to COVID-19 in recipients of kidney transplants

Sophie Caillard et al.

KIDNEY INTERNATIONAL (2020)

Add to Collection
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.